PMID- 36796472
OWN - NLM
STAT- MEDLINE
DCOM- 20230418
LR  - 20240502
IS  - 1873-7528 (Electronic)
IS  - 0149-7634 (Print)
IS  - 0149-7634 (Linking)
VI  - 148
DP  - 2023 May
TI  - Early auditory processing dysfunction in schizophrenia: Mechanisms and 
      implications.
PG  - 105098
LID - S0149-7634(23)00067-2 [pii]
LID - 10.1016/j.neubiorev.2023.105098 [doi]
AB  - Schizophrenia is a major mental disorder that affects approximately 1% of the 
      population worldwide. Cognitive deficits are a key feature of the disorder and a 
      primary cause of long-term disability. Over the past decades, significant 
      literature has accumulated demonstrating impairments in early auditory perceptual 
      processes in schizophrenia. In this review, we first describe early auditory 
      dysfunction in schizophrenia from both a behavioral and neurophysiological 
      perspective and examine their interrelationship with both higher order cognitive 
      constructs and social cognitive processes. Then, we provide insights into 
      underlying pathological processes, especially in relationship to glutamatergic 
      and N-methyl-D-aspartate receptor (NMDAR) dysfunction models. Finally, we discuss 
      the utility of early auditory measures as both treatment targets for precision 
      intervention and as translational biomarkers for etiological investigation. 
      Altogether, this review points out the crucial role of early auditory deficits in 
      the pathophysiology of schizophrenia, in addition to major implications for early 
      intervention and auditory-targeted approaches.
CI  - Copyright (c) 2023 Elsevier Ltd. All rights reserved.
FAU - Donde, Clement
AU  - Donde C
AD  - Univ. Grenoble Alpes, F-38000 Grenoble, France; INSERM, U1216, F-38000 Grenoble, 
      France; Psychiatry Department, CHU Grenoble Alpes, F-38000 Grenoble, France; 
      Psychiatry Department, CH Alpes-Isere, F-38000 Saint-Egreve, France. Electronic 
      address: clement.donde@univ-grenoble-alpes.fr.
FAU - Kantrowitz, Joshua T
AU  - Kantrowitz JT
AD  - Department of Psychiatry, Columbia University, 1051 Riverside Drive, New York, NY 
      10032, United States; Schizophrenia Research Center, Nathan Kline Institute, 140 
      Old Orangeburg Road, Orangeburg, NY 10962, United States.
FAU - Medalia, Alice
AU  - Medalia A
AD  - New York State Psychiatric Institute, Department of Psychiatry, Columbia 
      University Vagelos College of Physicians and Surgeons and New York Presbyterian, 
      New York, NY 10032, United States.
FAU - Saperstein, Alice M
AU  - Saperstein AM
AD  - New York State Psychiatric Institute, Department of Psychiatry, Columbia 
      University Vagelos College of Physicians and Surgeons and New York Presbyterian, 
      New York, NY 10032, United States.
FAU - Balla, Andrea
AU  - Balla A
AD  - Nathan Kline Institute for Psychiatric Research, Orangeburg, NY 10962, United 
      States.
FAU - Sehatpour, Pejman
AU  - Sehatpour P
AD  - Nathan Kline Institute for Psychiatric Research, Orangeburg, NY 10962, United 
      States; Division of Experimental Therapeutics, College of Physicians and 
      Surgeons, Columbia University, New York, NY, United States.
FAU - Martinez, Antigona
AU  - Martinez A
AD  - Nathan Kline Institute for Psychiatric Research, Orangeburg, NY 10962, United 
      States; Division of Experimental Therapeutics, College of Physicians and 
      Surgeons, Columbia University, New York, NY, United States.
FAU - O'Connell, Monica N
AU  - O'Connell MN
AD  - Translational Neuroscience Division, Center for Biomedical Imaging and 
      Neuromodulation, Nathan S. Kline Institute for Psychiatric Research, Orangeburg, 
      NY 10962, United States.
FAU - Javitt, Daniel C
AU  - Javitt DC
AD  - Nathan Kline Institute for Psychiatric Research, Orangeburg, NY 10962, United 
      States; Division of Experimental Therapeutics, College of Physicians and 
      Surgeons, Columbia University, New York, NY, United States. Electronic address: 
      dcj2113@cumc.columbia.edu.
LA  - eng
GR  - R01 MH049334/MH/NIMH NIH HHS/United States
GR  - R01 MH123142/MH/NIMH NIH HHS/United States
GR  - R33 MH116093/MH/NIMH NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Review
DEP - 20230214
PL  - United States
TA  - Neurosci Biobehav Rev
JT  - Neuroscience and biobehavioral reviews
JID - 7806090
RN  - 0 (Receptors, N-Methyl-D-Aspartate)
SB  - IM
MH  - Humans
MH  - *Schizophrenia
MH  - *Cognition Disorders/etiology
MH  - *Psychotic Disorders/complications
MH  - Auditory Perception/physiology
MH  - *Cognitive Dysfunction/complications
MH  - Receptors, N-Methyl-D-Aspartate
PMC - PMC10106448
MID - NIHMS1881326
OTO - NOTNLM
OT  - Auditory
OT  - Event-related potentials
OT  - NMDA receptor
OT  - Schizophrenia
OT  - Tone-matching
COIS- Conflicts of interest statement DCJ holds equity in Glytech, AASI and NRX pharma. 
      He has served as a consultant for SK Life Sciences, Biogen, Boehringer Ingelheim, 
      Autifony and Anavex. He has received research support from Cerevance. He holds 
      intellectual property for use of NMDAR agonists in treatment of schizophrenia; 
      NMDAR antagonists for treatment of depression; neurophysiological measures for 
      detection of amyloid deposition; and parcel-guided approaches to brain 
      stimulation. JTK reports having received consulting payments within the last 24 
      months from Alphasights, Medscape, Putnam, techspert.io, Health Monitor, Third 
      Bridge, MEDACorp, Trinity, Globaldata, GKA, Clearview, Clarivate, Health 
      Advances, ECRI Institute, ExpertConnect, Acsel Health, Slingshot, Antheum, 
      Guidepoint, L.E.K., SmartAnalyst, First Thought, Wedbush, Jefferies, Otsuka, Vox 
      Neuro and Reckner. He has served on the MedinCell Psychiatry, Tolmar, Merck, Leal 
      and the Karuna Advisory Boards. He has conducted clinical research supported by 
      the NIMH, Sunovion, Roche, Cerevance, Click, Neurocrine, Corcept, Taisho and 
      Boehringer Ingelheim within the last 24 months. He owns a small number of shares 
      of common stock from GSK. AM serves as a consultant at Boehringer Ingelheim and 
      Sumitomo and receives royalties from Oxford University Press. Other authors 
      report no potential COI.
EDAT- 2023/02/17 06:00
MHDA- 2023/04/18 06:42
PMCR- 2024/05/01
CRDT- 2023/02/16 19:23
PHST- 2022/11/02 00:00 [received]
PHST- 2023/02/08 00:00 [revised]
PHST- 2023/02/13 00:00 [accepted]
PHST- 2023/04/18 06:42 [medline]
PHST- 2023/02/17 06:00 [pubmed]
PHST- 2023/02/16 19:23 [entrez]
PHST- 2024/05/01 00:00 [pmc-release]
AID - S0149-7634(23)00067-2 [pii]
AID - 10.1016/j.neubiorev.2023.105098 [doi]
PST - ppublish
SO  - Neurosci Biobehav Rev. 2023 May;148:105098. doi: 10.1016/j.neubiorev.2023.105098. 
      Epub 2023 Feb 14.